Coya Therapeutics, Inc. (COYA)
(Delayed Data from NSDQ)
$6.40 USD
-0.03 (-0.47%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $6.38 -0.02 (-0.31%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
COYA 6.40 -0.03(-0.47%)
Will COYA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for COYA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for COYA
EyePoint Pharmaceuticals (EYPT) Reports Q2 Loss, Misses Revenue Estimates
Coya Therapeutics, Inc. (COYA) Surges 10.7%: Is This an Indication of Further Gains?
COYA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Coya Therapeutics, Inc. (COYA) Outperforming Other Medical Stocks This Year?
Wall Street Analysts See a 144.73% Upside in Coya Therapeutics, Inc. (COYA): Can the Stock Really Move This High?
What Makes Coya Therapeutics, Inc. (COYA) a New Buy Stock
Other News for COYA
Coya Therapeutics (COYA) Maintains Buy Rating with Target Price of $18 | COYA Stock News
Coya Therapeutics (COYA) Research Sheds Light on PD Immune Dysfunction | COYA Stock News
Coya Therapeutics publishes new research study on progression of Parkinson's
Coya Therapeutics Announces Publication of Scientific Research Linking Inflammation and ...
Sixteen new option listings on July 23rd